ISRCTN10681798进行中（未招募）1 期
A phase I randomized, investigator and participant blind, adaptive, multiple-ascending dose, parallel and four-way crossover, placebo-controlled study to investigate the safety, tolerability, pharmacokinetics, pharmacodynamics, and drug interactions (with midazolam) of RO7308480 following oral administration in healthy participants
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 72
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 性别
- All
入选标准
- •1. Participants who are overtly healthy (defined by absence of evidence of any active
- •or chronic disease).
- •2. Body mass index (BMI) of 18.5 to 30 kilogram metered square (kg/m²) inclusive.
- •3. Affiliated with a social security scheme.
排除标准
- •1. Any condition or disease detected during the medical interview/physical examination that could relapse during or immediately after the study, or would render the participant unsuitable for the study, place the participant at undue risk, or interfere with the ability of the participant to complete the study, as determined by the Investigator.
- •2. History or evidence of any medical condition potentially altering the absorption, metabolism, or elimination of drugs. This includes a surgical history of the gastrointestinal tract affecting gastric motility or altering the gastrointestinal tract.
- •3. Use of any psychoactive medication, or medications known to have effects on central nervous system (CNS), or blood flow taken within 4 weeks prior to dosing with RO7308480.
- •4. Use of any psychoactive medication, or medications known to have effects on CNS or blood flow taken within 4 weeks (or within 5 × the elimination half-life of the medication, whichever is longer) prior to dosing with RO7308480.
- •5. History of convulsions (other than benign febrile convulsions of childhood) including epilepsy, or personal history of significant cerebral trauma or CNS infections (e.g., meningitis).
- •6. Part 2 only: abnormalities in the brain known at time of screening which would adversely affect the MRI data analysis.
- •7. Part 2 only: any condition or disease detected during the medical interview/physical examination which are contraindications for lorazepam such as acute narrow-angle glaucoma, hypersensitivity to benzodiazepines or to any of the other ingredients, acute pulmonary insufficiency: respiratory depression; sleep apnea (risk of further respiratory depression), obsessional states (inadequate evidence of safety and efficacy), severe hepatic insufficiency (may precipitate encephalopathy) and/or myasthenia gravis.
- •8. Participation in an investigational drug or device study within 90 days (or within 5 times the elimination half-life of the investigational drug, whichever is longer) prior to screening, as calculated from the day of follow-up from the previous study, or more than 4 times per year.
- •9. Dietary restrictions that would prohibit the consumption of standardized meals.
- •10. Sensitivity to any of the study treatments, or components thereof, or drug or other allergy that contraindicates the participation in the study.
- •11. Aspartate aminotransferase (AST), alanine aminotransferase (ALT) and/or total bilirubin outside of normal range (with the exception of Gilbert’s syndrome with total bilirubin < 2.5 x upper limits of normal (ULN)).
- •12. Current or chronic history of liver disease or known hepatic or biliary abnormalities (with the exception of Gilbert’s syndrome with total bilirubin < 2.5 x ULN).
- •13. History of suicidal behavior or any risk of suicidal behavior in the opinion of a certified clinician or as evidenced by a yes” to questions 4 and/or 5 of columbia-suicide severity rating scale (C-SSRS) taken at screening.
- •14. Coffee (including caffeinated soft drinks or tea) consumption > 5 cups per day or methylxanthine (e.g., Coca-Cola) containing drinks > 1 liter/day or > 250 grams/day of chocolate.
- •15. Participants under judicial supervision, guardianship, or curatorship.
- •16. Part 2 only: any con
研究者
相似试验
进行中（未招募）
1 期
A study to evaluate the safety, tolerability, disposition in the body, and effects on the body of RO7504109 in healthy participantsHealthy volunteersISRCTN15555964F. Hoffmann-La Roche Ltd128
进行中（未招募）
1 期
Study to evaluate the safety, tolerability, and effect of the body and food on RO7308480 following oral administration in healthy participantsISRCTN63295298F. Hoffmann-La Roche Ltd96
进行中（未招募）
1 期
A study to evaluate the safety, tolerability, and processing by the body of single-ascending doses of RO7490677 in healthy participantsISRCTN12950872F. Hoffmann-La Roche Ltd24
进行中（未招募）
1 期
A Study of LY3541860 in Healthy Japanese and Non-Japanese ParticipantsHealthy ParticipantsJPRN-jRCT2031210359Wakayama Naohiko90
招募中
1 期
A Phase 1 study to evaluate the safety, tolerability, and pharmacokinetics of TIN816 in Japanese healthy participantsJPRN-jRCT2051230105Hirano Takamitsu24